临床与病理杂志2025，Vol.45Issue(2)：204-211,8.DOI:10.11817/j.issn.2095-6959.2025.230116
维奈克拉与淋系肿瘤
Venetoclax and lymphoid neoplasms
摘要
Abstract
Venetoclax is a selective B-cell lymphoma-2(Bcl-2)inhibitor that has been widely applied in the treatment of myeloid neoplasms,including acute myeloid leukemia,myelodysplastic syndrome,and certain lymphoid malignancies such as chronic lymphocytic leukemia/small lymphocytic lymphoma,with promising therapeutic outcomes.Venetoclax exerts its antitumor effect by binding to the Bcl-2 protein,displacing pro-apoptotic proteins,increasing mitochondrial outer membrane permeability,and activating caspase activity,thereby initiating the intrinsic mitochondrial apoptosis pathway and transforming the treatment paradigm of these diseases.Beyond the above-mentioned indications,venetoclax has also shown unique advantages and efficacy when used alone or in combination with other chemotherapeutic agents in other lymphoid neoplasms such as Hodgkin and non-Hodgkin lymphomas,as well as plasma cell neoplasms.Reported adverse effects include tumor lysis syndrome,myelosuppression,and associated life-threatening infections.However,its limited ability to inhibit Bcl-2 protein all subtypes remains a challenge to its broader efficacy.关键词
B细胞淋巴瘤-2/抑制剂/维奈克拉/淋系肿瘤/化学治疗Key words
B-cell lymphoma 2/inhibitor/venetoclax/lymphoid neoplasms/chemotherapy引用本文复制引用
周小代,朱慧敏,齐林,付建珠,王梦,杨静,成志勇..维奈克拉与淋系肿瘤[J].临床与病理杂志,2025,45(2):204-211,8.基金项目
河北省重点研发计划(223777105D).This work was supported by the Key Research and Development Project of Hebei Province,China(223777105D). （223777105D）
